Search Result

Results for "

SCID

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (6) Bcl-2 Family (2) Biochemical Assay Reagents (1) Cytochrome P450 (3) Discoidin Domain Receptor (1) E1/E2/E3 Enzyme (2) Estrogen Receptor/ERR (1) FGFR (1) FLT3 (1) Glutaminase (1) Histone Acetyltransferase (1) Integrin (1) IRAK (1) MDM-2/p53 (2) Microtubule/Tubulin (3) Mitochondrial Metabolism (1) NEKs (1) Oxidative Phosphorylation (1) Parasite (3) PDGFR (1) PERK (1) Pim (1) PROTACs (2) RAR/RXR (3) Ser/Thr Protease (1) TGF-β Receptor (1) Trk Receptor (1)
By Research Areas:	Cancer (25) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (5) Metabolic Disease (4)

By Targets:

Akt (1)

Apoptosis (6)

Bcl-2 Family (2)

Biochemical Assay Reagents (1)

Cytochrome P450 (3)

Discoidin Domain Receptor (1)

E1/E2/E3 Enzyme (2)

Estrogen Receptor/ERR (1)

FGFR (1)

FLT3 (1)

Glutaminase (1)

Histone Acetyltransferase (1)

Integrin (1)

IRAK (1)

MDM-2/p53 (2)

Microtubule/Tubulin (3)

Mitochondrial Metabolism (1)

NEKs (1)

Oxidative Phosphorylation (1)

Parasite (3)

PDGFR (1)

PERK (1)

Pim (1)

PROTACs (2)

RAR/RXR (3)

Ser/Thr Protease (1)

TGF-β Receptor (1)

Trk Receptor (1)

By Research Areas:

Cancer (25)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (5)

Metabolic Disease (4)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W018723

4-Aminobenzamidine dihydrochloride 1 Publications Verification p-Aminobenzamidine dihydrochloride	Ser/Thr Protease	Cancer
4-Aminobenzamidine (p-Aminobenzamidine) dihydrochloride is a strong trypsin inhibitor, also acting as a relatively weak urokinase type plasminogen activator (uPA) inhibitor (K_i=82 μM). 4-Aminobenzamidine can inhibit growth of a human prostate tumor in SCID mice .

HY-P99588

Stamulumab MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

HY-149428

AD4 1 Publications Verification	PROTACs	Cancer
AD4 is an artemisinin derivative that is a proteolytic targeting chimera (PROTAC) targeting PCLAF. AD4 can effectively degrade PCLAF in RS4;11 cells (IC₅₀: 0.6 nM), thereby activating the p21/Rb axis and exerting anti-tumor activity. AD4 also prolonged survival of RS4;11-transplanted NOD/SCID mice, with in vivo efficacy .

HY-P2300

Cyclo(Arg-Gly-Asp-D-Phe-Cys) Cyclo(RGDfC)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .

HY-106019C

Liarozole dihydrochloride R75251 dihydrochloride	Cytochrome P450 RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC₅₀=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties .

HY-106019

Liarozole R75251	Cytochrome P450 RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC₅₀=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties .

HY-158421

MS-L6	Oxidative Phosphorylation Mitochondrial Metabolism	Cancer
MS-L6 is a potent inhibitor of oxidative phosphorylation (OXPHOS) that can acts as electron transport chain complexes I (ETC-I) combining inhibition of NADH oxidation and uncoupling effect .

HY-W099584

Butyl tetradecanoate Myristic SCID butyl ester	Biochemical Assay Reagents	Others
Butyl tetradecanoate is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-163766

Antiproliferative agent-51	Estrogen Receptor/ERR	Cancer
Antiproliferative agent-51 (Compound 18h) exhibits inhibitory efficacy against estrogen receptor α (ERα) mediated transcription, with an IC₅₀ of 1.6 nM. Antiproliferative agent-51 inhibits the proliferation of cancer cell ZR-75, with an IC₅₀ of 0.031 μM. Antiproliferative agent-51 exhibits antitumor efficacy in mouse models .

HY-118912

BMH-9	Others	Inflammation/Immunology Cancer
BMH-9 (Compound Z54) is a modulator for nuclear receptor subfamily 2, group F, member 6 (NR2F6) (also known as nuclear orphan receptor Ear2) . BMH-9 is an activator for p53 signaling pathway through interaction with DNA. BMH-9 inhibits proliferation of human cancer cells, exhibits antitumor efficacy in NOD-SCID mouse models .

HY-106019A

Liarozole hydrochloride R75251 hydrochloride	Cytochrome P450 RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
Liarozole hydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole hydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC₅₀=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole hydrochloride shows antitumoral properties .

HY-120561

PC-046	Trk Receptor IRAK Pim Apoptosis	Cancer
PC-046 is a multi-target inhibitor for tyrosine receptor kinase B (TrkB), IRAK-4 and Pim-1, with IC₅₀ of 13.4 μM, 15.4 μM and 19.1 μM, respectively. PC-046 exhibits cytotoxicity against pancreatic cancer cell BxPC3 with IC₅₀ of 7.5-130 nM. PC-046 induces apoptosis and arrests cell cycle at G2/M phase in BxPC3. PC-046 exhibits antitumor efficacy and exhibits good pharmacokinetic characteristics in mice .

HY-114311

FGFR1/DDR2 inhibitor 1 1 Publications Verification	FGFR Discoidin Domain Receptor	Cancer
FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC₅₀ values of 31.1 nM and 3.2 nM, respectively. Antitumor activity .

HY-118748

Suprafenacine SRF	Microtubule/Tubulin	Cancer
Suprafenacine is a cell permeable, tubulin-destabilizing molecule which bind microtubules at the colchicine-binding site and inhibit polymerization. Suprafenacine can induce G2/M cell cycle arrest and apoptosis, and can be used for cancer research .

HY-164039

Talorasib	Others	Cancer
Talorasib (compound 1-2) has antitumor activity .

HY-158776

SLU-10482	Parasite	Infection
SLU-10482 is an orally active anti-parasitic agent, that inhibits Cryptosporidium parvum with an IC₅₀ of 0.0687 μM. SLU-10482 exhibits anti-infective efficacy in C. parvum infected mice with an AC₅₀ of 0.0686 μM .

HY-125858

MI-1061 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-125858A

MI-1061 TFA 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-153065

KIF18A-IN-6	Microtubule/Tubulin	Cancer
KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC₅₀ of 0.016 μM against KIF18A microtubule-dependent ATPase activity .

HY-153066

KIF18A-IN-7	Microtubule/Tubulin	Cancer
KIF18A-IN-7 (Compound 22) is an orally active KIF18A inhibitor with an IC₅₀ of 9.4 nM against KIF18A microtubule-dependent ATPase activity .

HY-158113

CBPD-409	Histone Acetyltransferase PROTACs	Cancer
CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC₅₀ of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC₅₀s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .

HY-136704

GLS1 Inhibitor-1	Glutaminase	Cancer
GLS1 Inhibitor-1 (Compound 27) is an orally active inhibitor for glutaminase 1 (GLS1) with an IC₅₀ of 0.021 μM. GLS1 Inhibitor-1 inhibits the proliferation of PC-3 with an IC₅₀ of 0.3 nM. GLS1 Inhibitor-1 exhibits antitumor efficacy against NCI-H1703 with GI₅₀ of 0.011 μM. GLS1 Inhibitor-1 exhibits moderate pharmacokinetic characteristics .

HY-161905

ML471	Parasite	Infection
ML471 is an oral active parasite tyrosyl-tRNA synthetase (PfTyrRS) inhibitor and can be used for study of malaria .

HY-13846

BM-1074	Bcl-2 Family Apoptosis	Cancer
BM-1074 is a potent and specific Bcl-2/Bcl-xL inhibitor with K_i values of < 1 nM and IC₅₀ values of 1.8 nM and 6.9 nM for Bcl-2 and Bcl-xL, respectively. BM-1074 induces apoptosis, and exhibits antiproliferative activity against four small-cell lung cancer cell lines (H146, H1963, H187 and H1417) with IC₅₀ values of 1-2 nM .

HY-163483

ELQ-598	Parasite	Others
ELQ-598, as a prodrug, is converted into the active drug ELQ-596 upon oral administration. ELQ-598 demonstrates potent parasitic growth inhibition capabilities (IC₅₀= 37 nM). ELQ-598 also shows low toxicity towards human cells (IC₅₀= 19 μM). ELQ-598 can be used for research into babesiosis .

HY-112417

Ki11502	PDGFR FLT3 Apoptosis Akt PERK Bcl-2 Family	Cardiovascular Disease Cancer
Ki11502 is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGF β/α receptors with IC₅₀ values less than 10 nM. Ki11502 selectively inhibits PDGF β receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Ki11502 can induce Apoptosis) and exhibits profound antiproliferative effects on select subsets of leukemia, including those with Imatinib (HY-15463) resistant mutations. Ki11502 is highly suitable for studying the role of PDGF in vascular diseases, particularly the role of proteoglycans in atherosclerosis .

HY-120356

T-1101 TAI-95	Apoptosis NEKs	Cancer
T-1101 (TAI-95) is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 blocks the interaction between Hec1 and NEK2, exhibits cytotoxicity in human liver cancer cells with GI₅₀ of 15-70 nM. T-1101 induces apoptosis in Huh-7. T-1101 exhibits antitumor efficacy in mouse models .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library	464 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 464 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

JAK/STAT Compound Library

464 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 464 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Butyl tetradecanoate Myristic SCID butyl ester	Biochemical Assay Reagents
Butyl tetradecanoate is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Cat. No.	Product Name	Target	Research Area

HY-P2300

Cyclo(Arg-Gly-Asp-D-Phe-Cys) Cyclo(RGDfC)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .

HY-P10301

CXCL9(74-103)	Peptides	Cancer
CXCL9(74-103) is a derivative peptide of CXCL9 that has a high affinity for glycosaminoglycans (GAGs) and can bind to GAGs. CXCL9(74-103) possesses anti-angiogenic properties, capable of reducing EGF, VEGF165, and FGF-2-mediated angiogenesis processes in vitro, without exhibiting cytotoxicity .

Cat. No.	Product Name	Target	Research Area

HY-P99488

Briquilimab JSP-191	Inhibitory Antibodies	Inflammation/Immunology Cancer
Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID) .

HY-P99588

Stamulumab MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

HY-P99212

Otlertuzumab TRU-016	Inhibitory Antibodies	Cancer
Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research .

Briquilimab JSP-191	Classification of Application Fields Disease Research Fields Cancer	Others
Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID) .

Otlertuzumab TRU-016	Classification of Application Fields Disease Research Fields Cancer	Others
Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks